PNU-142731A Pharmacia
- PMID: 11249698
PNU-142731A Pharmacia
Abstract
Pharmacia is developing PNU-142731A, a potential lead compound as a treatment for asthma [294718]. It is in phase I clinical trials. PNU-142731A is a potent inhibitor of eosinophilic lung inflammation in rodents, and shows a good bioavailability profile in animals; the mechanism of action is being investigated. Unlike the original compound PNU-104067F, PNU-142731A does not give rise to gall bladder toxicity [295987], [298023].
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical